WBDE(SZ:002082) Quan Jing Wang·2025-11-28 03:07Core Insights - The company is deeply engaged in the research and development of new drugs for Alzheimer's disease (AD), aiming to create new treatment options for global AD patients [1][2] - The key registration clinical trial for the company's controlled-release donepezil tablets (FN12) is progressing smoothly, being the largest known AD registration study in China [1] - Preliminary data indicates that the controlled-release donepezil tablets have good safety profiles and can significantly improve cognitive function in patients [1] - The company is also developing a new class of peptide drugs targeting different mechanisms, showing promising results in preclinical studies for weight loss and other metabolic benefits [1][2] Alzheimer's Disease Research - The company has been conducting extensive research on Alzheimer's disease, with a focus on the controlled-release donepezil tablets, which are currently in Phase II/III clinical trials [1] - Collaboration with CROs is emphasized to expedite the acquisition of effective data to validate the drug's efficacy and safety [1] - The controlled-release donepezil tablets are believed to offer differentiated clinical benefits due to their multifaceted actions, including anti-inflammatory and neuroprotective effects [1] New Drug Development - The company is advancing its peptide drug project, which is a new compound targeting melanocortin receptors, showing excellent weight loss effects in preclinical animal studies [1] - The peptide drug also demonstrates potential in lowering blood sugar levels and improving indicators related to diabetic complications [1] - The company has received orphan drug designation from the FDA for this peptide drug, indicating its potential significance in treating rare diseases [1]